Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial. Molina, J., Rizzardini, G., Orrell, C., Afani, A., Calmy, A., Oka, S., Hinestrosa, F., Kumar, P., Tebas, P., Walmsley, S., Grandhi, A., Klopfer, S., Gendrano, I., Eves, K., Correll, T. A, Fox, M. C, & Kim, J. The Lancet HIV, 11(6):e369–e379, June, 2024. ![Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi bibtex @article{molina_switch_2024,
title = {Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with {HIV}-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial},
volume = {11},
issn = {23523018},
shorttitle = {Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with {HIV}-1 on antiretroviral therapy},
url = {https://linkinghub.elsevier.com/retrieve/pii/S2352301824000316},
doi = {10.1016/S2352-3018(24)00031-6},
language = {en},
number = {6},
urldate = {2025-06-24},
journal = {The Lancet HIV},
author = {Molina, Jean-Michel and Rizzardini, Giuliano and Orrell, Catherine and Afani, Alejandro and Calmy, Alexandra and Oka, Shinichi and Hinestrosa, Federico and Kumar, Princy and Tebas, Pablo and Walmsley, Sharon and Grandhi, Anjana and Klopfer, Stephanie and Gendrano, Isaias and Eves, Karen and Correll, Todd A and Fox, Michelle C and Kim, Jason},
month = jun,
year = {2024},
pages = {e369--e379},
}
Downloads: 0
{"_id":"ksSo5WmcGbpohfFWN","bibbaseid":"molina-rizzardini-orrell-afani-calmy-oka-hinestrosa-kumar-etal-switchtofixeddosedoravirine100mgwithislatravir075mgoncedailyinvirologicallysuppressedadultswithhiv1onantiretroviraltherapy48weekresultsofaphase3randomisedopenlabelnoninferioritytrial-2024","author_short":["Molina, J.","Rizzardini, G.","Orrell, C.","Afani, A.","Calmy, A.","Oka, S.","Hinestrosa, F.","Kumar, P.","Tebas, P.","Walmsley, S.","Grandhi, A.","Klopfer, S.","Gendrano, I.","Eves, K.","Correll, T. A","Fox, M. C","Kim, J."],"bibdata":{"bibtype":"article","type":"article","title":"Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial","volume":"11","issn":"23523018","shorttitle":"Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy","url":"https://linkinghub.elsevier.com/retrieve/pii/S2352301824000316","doi":"10.1016/S2352-3018(24)00031-6","language":"en","number":"6","urldate":"2025-06-24","journal":"The Lancet HIV","author":[{"propositions":[],"lastnames":["Molina"],"firstnames":["Jean-Michel"],"suffixes":[]},{"propositions":[],"lastnames":["Rizzardini"],"firstnames":["Giuliano"],"suffixes":[]},{"propositions":[],"lastnames":["Orrell"],"firstnames":["Catherine"],"suffixes":[]},{"propositions":[],"lastnames":["Afani"],"firstnames":["Alejandro"],"suffixes":[]},{"propositions":[],"lastnames":["Calmy"],"firstnames":["Alexandra"],"suffixes":[]},{"propositions":[],"lastnames":["Oka"],"firstnames":["Shinichi"],"suffixes":[]},{"propositions":[],"lastnames":["Hinestrosa"],"firstnames":["Federico"],"suffixes":[]},{"propositions":[],"lastnames":["Kumar"],"firstnames":["Princy"],"suffixes":[]},{"propositions":[],"lastnames":["Tebas"],"firstnames":["Pablo"],"suffixes":[]},{"propositions":[],"lastnames":["Walmsley"],"firstnames":["Sharon"],"suffixes":[]},{"propositions":[],"lastnames":["Grandhi"],"firstnames":["Anjana"],"suffixes":[]},{"propositions":[],"lastnames":["Klopfer"],"firstnames":["Stephanie"],"suffixes":[]},{"propositions":[],"lastnames":["Gendrano"],"firstnames":["Isaias"],"suffixes":[]},{"propositions":[],"lastnames":["Eves"],"firstnames":["Karen"],"suffixes":[]},{"propositions":[],"lastnames":["Correll"],"firstnames":["Todd","A"],"suffixes":[]},{"propositions":[],"lastnames":["Fox"],"firstnames":["Michelle","C"],"suffixes":[]},{"propositions":[],"lastnames":["Kim"],"firstnames":["Jason"],"suffixes":[]}],"month":"June","year":"2024","pages":"e369–e379","bibtex":"@article{molina_switch_2024,\n\ttitle = {Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with {HIV}-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial},\n\tvolume = {11},\n\tissn = {23523018},\n\tshorttitle = {Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with {HIV}-1 on antiretroviral therapy},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S2352301824000316},\n\tdoi = {10.1016/S2352-3018(24)00031-6},\n\tlanguage = {en},\n\tnumber = {6},\n\turldate = {2025-06-24},\n\tjournal = {The Lancet HIV},\n\tauthor = {Molina, Jean-Michel and Rizzardini, Giuliano and Orrell, Catherine and Afani, Alejandro and Calmy, Alexandra and Oka, Shinichi and Hinestrosa, Federico and Kumar, Princy and Tebas, Pablo and Walmsley, Sharon and Grandhi, Anjana and Klopfer, Stephanie and Gendrano, Isaias and Eves, Karen and Correll, Todd A and Fox, Michelle C and Kim, Jason},\n\tmonth = jun,\n\tyear = {2024},\n\tpages = {e369--e379},\n}\n\n\n\n","author_short":["Molina, J.","Rizzardini, G.","Orrell, C.","Afani, A.","Calmy, A.","Oka, S.","Hinestrosa, F.","Kumar, P.","Tebas, P.","Walmsley, S.","Grandhi, A.","Klopfer, S.","Gendrano, I.","Eves, K.","Correll, T. A","Fox, M. C","Kim, J."],"key":"molina_switch_2024","id":"molina_switch_2024","bibbaseid":"molina-rizzardini-orrell-afani-calmy-oka-hinestrosa-kumar-etal-switchtofixeddosedoravirine100mgwithislatravir075mgoncedailyinvirologicallysuppressedadultswithhiv1onantiretroviraltherapy48weekresultsofaphase3randomisedopenlabelnoninferioritytrial-2024","role":"author","urls":{"Paper":"https://linkinghub.elsevier.com/retrieve/pii/S2352301824000316"},"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://bibbase.org/zotero-group/Yulisha27/6024450","dataSources":["PNS53NAAhKDwHWBCi"],"keywords":[],"search_terms":["switch","fixed","dose","doravirine","100","islatravir","once","daily","virologically","suppressed","adults","hiv","antiretroviral","therapy","week","results","phase","randomised","open","label","non","inferiority","trial","molina","rizzardini","orrell","afani","calmy","oka","hinestrosa","kumar","tebas","walmsley","grandhi","klopfer","gendrano","eves","correll","fox","kim"],"title":"Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial","year":2024}